The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | The role of PHF19 in multiple myeloma & its potential as a therapeutic target
Tengteng Yu, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the impact of PHF19 overexpression in multiple myeloma, commenting on the results of a recent study that reported that PHF19 overexpression induces resistance to anti-CD38 monoclonal antibodies and increases regulatory T-cell levels in patients treated with CAR-T therapy, and highlighting the potential of PHF19 as a therapeutic target in multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
